Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.r.l. Irccs
Clinical trials sponsored by Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.r.l. Irccs, explained in plain language.
-
New study aims to better time palliative care for advanced illnesses
Knowledge-focused CompletedThis study looked at 178 people with advanced cancer, chronic kidney disease, or chronic lung disease to find out when they need palliative care. Researchers used special scores to see if care was given at the right time. No extra treatments or visits were added—just observation …
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated May 26, 2026 03:28 UTC
-
Can a smartphone app beat a paper diary for cancer pill reminders?
Knowledge-focused CompletedThis study tested whether using an electronic diary (app) helps cancer patients take their oral medications more consistently than a paper diary. 124 adults with solid tumors or blood cancers participated. Researchers compared pill counts between the two groups to see which metho…
Phase: NA • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated May 26, 2026 03:04 UTC
-
Italian study reviews Real-World use of targeted leukemia drug
Knowledge-focused CompletedThis study looked back at the medical records of 84 people with acute lymphoblastic leukemia (ALL) who received a drug called anti-CD22 outside of clinical trials in Italy. The goal was to learn more about the drug's side effects, how well it worked, and its costs in everyday hos…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated May 19, 2026 11:59 UTC